News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A Skeptical Take on Eli Lilly and Company (LLY)


10/15/2012 8:23:49 AM

My e-mail inbox has been filled with some very bullish takes on Eli Lilly and its Alzheimer’s drug solanezumab. There’s also a lot of excitement about the idea that the patent for Alimta, a top-selling cancer drug, might hold up in court, extending a very profitable franchise for the drug maker. But here is the opposite take, from Cowen and Co. analyst Steven Scala who downgraded Lilly stock to underperform today.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES